Mazdutide clinical trials
Also written IBI362 and LY3305677.
ClinicalTrials.gov finds 45 studies for mazdutide. How that becomes 44 here
Every study that search finds has been read, to see whether and how it gives mazdutide. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 45Found by its intervention search · See all 45 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 21 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 46Give mazdutide to participants
- −2Compare another treatment with it
- 44Test it: the count on this site
Get an email when these change. Save the mazdutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2026 (14); 1 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 9 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 17
Innovent Biologics (Suzhou) Co. Ltd. (20) · Eli Lilly and Company (7) · Shanghai Zhongshan Hospital (2) · Tongji Hospital (2) · Peking University People's Hospital (1) · Beijing Anzhen Hospital (1) · Hongwei Jiang (1) · The Second Affiliated Hospital of Chongqing Medical University (1)
Often tested with
Tested in the same studies.
Dulaglutide (1) · Atorvastatin (1) · Finerenone (1) · Eloralintide (1) · Naperiglipron (1) · Macupatide (1) · Semaglutide (1) · Tirzepatide (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Mazdutide is the comparator. A study of two new drugs counts under both.
- 1HDM1005 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · next primary completion Aug 2027
Reaching primary completion within a year · 5, 3 in phase 3
Studies that test mazdutide, phase 3 first.
- Dec 2026A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Phase 3 · Innovent Biologics (Suzhou) Co. Ltd.
- May 2027A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2Phase 3 · Innovent Biologics (Suzhou) Co. Ltd.
- Oct 2027A Study of IBI362 in Chinese Adolescents With Obesity or OverweightPhase 3 · Innovent Biologics (Suzhou) Co. Ltd.
- Sep 2027A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPhase 2 · Eli Lilly and Company
- Sep 2027Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNot applicable · Beijing Friendship Hospital
Studies
Open first, then newest update. How each study uses mazdutide has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 44
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementRecruitingNot applicableShanghai Zhongshan HospitalNCT07517042Continued or stopped, with or without intensive lifestyle support, to keep weight offWritten as MazdutideReport a problem
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyRecruitingPhase 4Huijie ZhangNCT07775846With or without finerenone in diabetic kidney diseaseWritten as MazdutideReport a problem
- Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 DiabetesNot yet recruitingNot applicablePeking University People's HospitalNCT07924553Against placebo in type 1 diabetesWritten as MazdutideReport a problem
- Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese PatientsNot yet recruitingNot applicableBeijing Anzhen HospitalNCT07897305Against usual care after atrial fibrillation ablationWritten as MazdutideReport a problem
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityRecruitingPhase 4China National Center for Cardiovascular DiseasesNCT07657676Against placebo on coronary plaque with obesityWritten as MazdutideReport a problem
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Against placebo in one appendix of a weight-loss master protocolWritten as LY3305677Report a problem
- Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)RecruitingPhase 4West China HospitalNCT07718126Against placebo before living liver donationWritten as MazdutideReport a problem
- Efficacy of Mazdutide on Fatty PancreasNot yet recruitingNot applicableTongji HospitalNCT07803705Against placebo for fatty pancreasWritten as mazdutideReport a problem
- Mazdutide for Weight Management and Gout in Adults With ObesityNot yet recruitingPhase 4Hongwei JiangNCT07824895Alone in obesity with goutWritten as MazdutideReport a problem
- Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)RecruitingPhase 3The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07083154Against placebo in type 2 diabetes with early cognitive impairmentWritten as MazdutideReport a problem
- Body-weight Reduction Effect on Portal Hypertension in Compensated CirrhosisNot yet recruitingNot applicableThe Second Affiliated Hospital of Chongqing Medical UniversityNCT07797101Alone in cirrhosis with portal hypertensionWritten as Mazdutide injectionReport a problem
- Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNot yet recruitingPhase 2Tongji HospitalNCT07781150Added to a hormonal IUD, against placebo, in early endometrial cancerWritten as Mazdutide(Dual GLP-1R/GCGR Agonist)Report a problem
- Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled TrialNot yet recruitingNot applicableYanbing LiNCT07767552Against placebo for type 2 diabetes remissionWritten as MazdutideReport a problem
- Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNot yet recruitingNot applicableTianjin Medical UniversityNCT07713992Switched to from semaglutide, in diabetes with fatty liverWritten as Mazdutide(Dual GLP-1R/GCGR Agonist)Report a problem
- Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)Not yet recruitingPhase 4Shandong Provincial HospitalNCT07654062Against placebo in prediabetesWritten as MazdutideReport a problem
- GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityRecruitingNot applicableChina-Japan Friendship HospitalNCT07633639One of three GLP-1 drugs after sleeve gastrectomyReport a problem
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07469800Against placebo for high blood pressure with obesityWritten as IBI362Report a problem
- A Study of IBI362 in Chinese Adolescents With Obesity or OverweightRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07255209Against placebo in teenagers with obesityWritten as IBI362Report a problem
- Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNot yet recruitingNot applicableBeijing Friendship HospitalNCT07135141Against placebo after sleeve gastrectomyReport a problem
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06931028Against placebo in sleep apnoea with obesityWritten as IBI362Report a problem
See all 44 studies that test mazdutide →
Tested on its own · 35 — no other medicine in its arm
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementRecruitingNot applicableShanghai Zhongshan HospitalNCT07517042Continued or stopped, with or without intensive lifestyle support, to keep weight offWritten as MazdutideReport a problem
- Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 DiabetesNot yet recruitingNot applicablePeking University People's HospitalNCT07924553Against placebo in type 1 diabetesWritten as MazdutideReport a problem
- Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese PatientsNot yet recruitingNot applicableBeijing Anzhen HospitalNCT07897305Against usual care after atrial fibrillation ablationWritten as MazdutideReport a problem
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityRecruitingPhase 4China National Center for Cardiovascular DiseasesNCT07657676Against placebo on coronary plaque with obesityWritten as MazdutideReport a problem
- Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)RecruitingPhase 4West China HospitalNCT07718126Against placebo before living liver donationWritten as MazdutideReport a problem
- Efficacy of Mazdutide on Fatty PancreasNot yet recruitingNot applicableTongji HospitalNCT07803705Against placebo for fatty pancreasWritten as mazdutideReport a problem
- Mazdutide for Weight Management and Gout in Adults With ObesityNot yet recruitingPhase 4Hongwei JiangNCT07824895Alone in obesity with goutWritten as MazdutideReport a problem
- Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)RecruitingPhase 3The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07083154Against placebo in type 2 diabetes with early cognitive impairmentWritten as MazdutideReport a problem
- Body-weight Reduction Effect on Portal Hypertension in Compensated CirrhosisNot yet recruitingNot applicableThe Second Affiliated Hospital of Chongqing Medical UniversityNCT07797101Alone in cirrhosis with portal hypertensionWritten as Mazdutide injectionReport a problem
- Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled TrialNot yet recruitingNot applicableYanbing LiNCT07767552Against placebo for type 2 diabetes remissionWritten as MazdutideReport a problem
- Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)Not yet recruitingPhase 4Shandong Provincial HospitalNCT07654062Against placebo in prediabetesWritten as MazdutideReport a problem
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07469800Against placebo for high blood pressure with obesityWritten as IBI362Report a problem
- A Study of IBI362 in Chinese Adolescents With Obesity or OverweightRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07255209Against placebo in teenagers with obesityWritten as IBI362Report a problem
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06931028Against placebo in sleep apnoea with obesityWritten as IBI362Report a problem
- A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Active, not recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06937749Against placebo in MASHWritten as IBI362Report a problem
- A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityActive, not recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06862908Against placebo in heart failure with obesityWritten as IBI362Report a problem
- Efficacy of Mazdutide for Treating PCOSCompletedPhase 1/2Shanghai Zhongshan HospitalNCT06519656Alone in women with PCOS and obesityWritten as MazdutideReport a problem
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderCompletedPhase 2Eli Lilly and CompanyNCT06817356Against placebo in alcohol use disorderWritten as MazdutideReport a problem
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06184568Against semaglutide in early type 2 diabetes with obesityWritten as IBI362Report a problem
- A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Active, not recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06884293Against semaglutide in fatty liver disease with obesityWritten as IBI362Report a problem
Showing 20 of 35. See all 35 →
Tested with established drugs · 3 — they are given beside it
- Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNot yet recruitingPhase 2Tongji HospitalNCT07781150Added to a hormonal IUD, against placebo, in early endometrial cancerWritten as Mazdutide(Dual GLP-1R/GCGR Agonist)Report a problem
- Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNot yet recruitingNot applicableTianjin Medical UniversityNCT07713992Switched to from semaglutide, in diabetes with fatty liverWritten as Mazdutide(Dual GLP-1R/GCGR Agonist)Report a problem
- Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMCompletedPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT04466904Repeated doses against placebo or dulaglutide in type 2 diabetesWritten as IBI362Report a problem
Tested in a combination · 6 — another drug in the study is under test too
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyRecruitingPhase 4Huijie ZhangNCT07775846With or without finerenone in diabetic kidney diseaseWritten as MazdutideReport a problem
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Against placebo in one appendix of a weight-loss master protocolWritten as LY3305677Report a problem
- GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityRecruitingNot applicableChina-Japan Friendship HospitalNCT07633639One of three GLP-1 drugs after sleeve gastrectomyReport a problem
- Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNot yet recruitingNot applicableBeijing Friendship HospitalNCT07135141Against placebo after sleeve gastrectomyReport a problem
- A Study of IBI362 in Participants With Type 2 DiabetesCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT05606913Against dulaglutide in type 2 diabetes on oral drugsWritten as IBI362Report a problem
- A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05815680Its effect on four other drugs' levelsWritten as IBI362Report a problem
As the comparator · 2 — what is tested is compared with mazdutide
- A Study of HRS-4729 Injection in Participants With Type 2 DiabetesNot yet recruitingPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07843862The comparator, against HRS-4729 in type 2 diabetesWritten as MazdutideReport a problem
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNot yet recruitingPhase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07417306The comparator, against HDM1005 in type 2 diabetesWritten as MazdutideReport a problem
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNov 10, 2026NCT07775846
Newly registered2
- Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 DiabetesNov 9, 2026NCT07924553
- Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese PatientsOct 27, 2026NCT07897305
Codes
What other systems call mazdutide · ClinicalTrials.gg INT001730
- MeSH (NLM) C000719829mazdutideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) MB76Z4IBZ5MAZDUTIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q123248554mazdutideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C186406MazdutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719829 | mazdutide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | MB76Z4IBZ5 | MAZDUTIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123248554 | mazdutide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C186406 | Mazdutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.